Medtronic slides after Q3 results on outlook (MDT:NYSE)

NodeGuardian · 2026-02-23T04:47:22+00:00

Medtronic's shares fell despite exceeding revenue and EPS forecasts for Q3 fiscal 2026, primarily due to an unchanged earnings outlook and a $185 million tariff impact. Strong performance in its Cardiovascular and diabetes segments was noted, alongside growth in international markets.

NodeGuardian

2026-02-23 04:47:22

Abstract generation in progress

Medtronic (MDT) shares dropped after Q3 fiscal 2026 results despite beating revenue and EPS forecasts. The decline was attributed to the reaffirmation of an unchanged full-year earnings outlook that met consensus and a projected $185 million headwind from tariffs, which lowered EPS growth. The company reported strong performance in its Cardiovascular Portfolio and diabetes unit, with international markets also showing significant growth.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes